Ultracet 37,5 mg/325 mg FC tablets
PDF Leaflet Revision Date: 01 September 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Management of moderate to moderately-severe pain in adults.
Dosage (summary)
1-2 tablets every 4-6 hours as needed, max 8 tablets/day.
Onset of Action / Duration
Onset: 30 mins, Duration: 6-8 hours
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy or lactation due to risks of respiratory depression in newborns.
Key Drug Interactions
- CNS depressants
- Serotonergic medicines
- MAO inhibitors
- Warfarin
Contraindications
- Hypersensitivity to tramadol or paracetamol
- Severe hepatic impairment
- Respiratory depression
- Epilepsy
- Children under 12 years
Common side effects
- Nausea
- Dizziness
- Somnolence
- Pruritus
- Rash
Counselling Points
- Do not exceed recommended dose
- Avoid alcohol
- Monitor for signs of respiratory depression
- Seek immediate help for overdose symptoms
Serious warnings
- Risk of respiratory depression
- Potential for dependence and abuse
- Seizures reported
Important Disclaimer
The Ultracet 37,5 mg/325 mg FC tablets professional information leaflet below is the property of Janssen Pharmaceutica and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
